Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

2019565 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet

Volume 394, Issue 10192, pp. 39-50

Field-Weighted Citation Impact: 42.55